We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Requests 36-Month Data for BMS’ Belatacept
FDA Requests 36-Month Data for BMS’ Belatacept
May 3, 2010
Bristol-Myers Squibb (BMS) has received a complete response letter from the FDA on belatacept, under review for prophylaxis of rejection in kidney transplant
recipients.